ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0097

The Human Lupus TREX1 D18N Mutation Engineered in C. Elegans Leads to Cell Death. What Can We Learn About Lupus Using C. Elegans?

Htay Htay Kyi1, Patricia Barreto2, Yeshaswi Pulijala3, Thejasvi Venkatachalam3 and Martha Soto2, 1Rutgers New Jersey Medical School, Jersey City, NJ, 2Robert Wood Johnson Medical School, Piscataway, NJ, 3RWJ-PATHOLOGY-RESEARCH-PISC, Piscataway

Meeting: ACR Convergence 2024

Keywords: Animal Model, Cell Death, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Animal Models Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: TREX1 gene encodes the three prime repair exonuclease 1 enzyme that degrades DNA. TREX1 plays a key role in genomic DNA degradation, cell death processes, and gap-filling during DNA repair. The most significant role of TREX1 is to maintain host innate immune tolerance to cytosolic self-DNA by degrading a range of substrates to prevent initiation of autoimmunity via regulation of cyclic GMP-AMP synthase(cGAS) – Stimulator of interferon Genes (STING) immune signaling. TREX1 mutations have been associated with autoimmune disorders, including Aicardi-Goutières Syndrome, familial chilblains lupus. However, it is unclear whether mutations in TREX1 play a causal role in the disease progression, and whether manipulation of TREX1 has a beneficial effect in the treatment of autoimmune diseases. The role of TREX-2 in DNA repair has been studied in C. elegans but not TREX-1. We proposed to study the mechanism of disease caused by TREX-1 mutations, linked to Lupus in C. elegans.

Methods: We found evidence that genomic sequence W02F12.4 in C. elegans is the ortholog of TREX1. We used CRISPR to recreate point mutations in the C. elegans TREX-1 gene and characterize their phenotypes. We also used RNAi (RNA interference) to deplete the TREX1 mRNA, by feeding C. elegans worms bacteria carrying double stranded RNA of the trex-1 gene. C. elegans has a well-studied receptor for apoptotic corpse clearance called CED-1. Based on sequence alignment, we proposed SCARF1 is an ortholog of CED-1. We used CED-1: GFP to detect signal around dying cells via live imaging.

Results: We used two methods to interfere with TREX1 function in C. elegans: RNAi depletion and CRISPR. 1. RNAi depletion: Three days after feeding C. elegans worms bacteria carrying double stranded RNA of the trex-1 gene, the progeny at the late embryonic “pretzel” stage had holes in the head and tail region. This “holes” phenotype looks like necrotic cell death. The dead cells are recognized by the CED-1/SCARF cell death receptors (Fig. 1). 2. CRISPR: We found that D18, K175, D 130 amino acids that are mutated in TREX1 in connection with Lupus were conserved in C. elegans via sequence alignment (Fig.2). We first created the D18N mutation in TREX-1. Similar to the RNAi results, we saw that some of the developing worms had holes, that appeared necrotic.  To test if the holes are necrotic, we tested if they depend on calreticulin, a protein that helps export Calcium from the endoplasmic reticulum during necrotic cell death. A mutation in calreticulin, crt-1, can block necrotic deaths. Feeding trex-1 RNAi to crt-1 worms showed a decrease in holes but did not completely block them (Table1).

Conclusion: Using C. elegans, a small model organism with existing tools for phenotypic analysis, live imaging of dying cells, and known genetics pathways that regulate corpse engulfment, we discovered that TREX-1 loss results in cell deaths that look necrotic. If further evidence supports that loss of TREX-1 causes necrotic death, we can investigate which pathways leading to necrotic death may be affected by the loss of TREX-1.  Knowing the exact pathway could identify molecular regulators of TREX1. It is possible that TREX1 mutations contribute to cell deaths that result in inflammation that contribute to autoimmunity.

Supporting image 1

Fig. 1. DIC (differential interference contrast) and CED_1:GFP (markers for the dying cells) images showed “ holes” (arrow heads) caused by trex_1 RNAi

Supporting image 2

Fig. 2. Human vs. Worm TREX1: some amino acids mutated in lupus are conserved in C. elegans TREX1 highlighted in yellow color, arrow indicating D18N

Supporting image 3


Disclosures: H. Kyi: None; P. Barreto: None; Y. Pulijala: None; T. Venkatachalam: None; M. Soto: None.

To cite this abstract in AMA style:

Kyi H, Barreto P, Pulijala Y, Venkatachalam T, Soto M. The Human Lupus TREX1 D18N Mutation Engineered in C. Elegans Leads to Cell Death. What Can We Learn About Lupus Using C. Elegans? [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-human-lupus-trex1-d18n-mutation-engineered-in-c-elegans-leads-to-cell-death-what-can-we-learn-about-lupus-using-c-elegans/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-human-lupus-trex1-d18n-mutation-engineered-in-c-elegans-leads-to-cell-death-what-can-we-learn-about-lupus-using-c-elegans/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology